Staphylococcus aureus and the skin: A longstanding and complex interaction

SKINmed

Volumn 13, Issue 2, 2015, Pages 111-119

  Becker, Russell E N ^a   Wardenburg, Juliane Bubeck ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE;

HUMAN; IMMUNOLOGY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PATHOGENICITY; PHYSIOLOGY; STAPHYLOCOCCAL SKIN INFECTION; STAPHYLOCOCCUS AUREUS; VIRULENCE;

BACTERIAL VACCINES; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS; VIRULENCE;

EID: 84938696362     PISSN: 15409740     EISSN: 17517125     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998;339:520–532.
2. McCaig LF, McDonald LC, Mandal S, Jernigan DB. Staphylococcus aureus–associated skin and soft tissue infections in ambulatory care. Emerg Infect Dis. 2006;12:1715–1723.
3. Gorwitz RJ, Jernigan DB, Jernigan JA, Powers JH; Participants in the CDC-Convened Experts’ Meeting on Management of MRSA in the Community. Strategies for clinical management of MRSA in the community: summary of an expert’s meeting convened by the Centers for Disease Control and Prevention. March. 2006. http://www.cdc.gov/ncidod/dhqp/ar_mrsa_ca.html.
4. Demos M, McLeod MP, Nouri K. Recurrent furunculosis: a review of the literature. Br J Dermatol. 2012;167:725–732.
5. Morgan M. Treatment of MRSA soft tissue infections: an overview. Injury. 2011;42 suppl 5:S11–S17.
6. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005;41:1373–1406.
7. Macias ES, Pereira FA, Rietkerk W, Safai B. Superantigens in dermatology. J Am Acad Dermatol. 2011;64:455–472; quiz 473–454.
8. Skov R, Christiansen K, Dancer SJ, et al. Update on the prevention and control of community-acquired meticillin- resistant Staphylococcus aureus (CA-MRSA). Int J Antimicrob Agents. 2012;39:193–200.
9. Moran GJ, Abrahamian FM, Lovecchio F, Talan DA. Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines. J Emerg Med. 2013;44:e397-e412.
10. Goetghebeur M, Landry PA, Han D, Vicente C. Methicillin- resistant Staphylococcus aureus: a public health issue with economic consequences. Can J Infect Dis Med Microbiol. 2007;18:27–34.
11. Centers for Disease Control and Prevention. Active bacterial core surveillance (abcs) report, emerging infections program network, methicillin-resistant Staphylococcus aureus, 2011. http://www.cdc.gov/abcs/reports-findings/survreports/mrsa11.pdf.
12. Otto M. MRSA virulence and spread. Cell Microbiol. 2012;14:1513–1521.
13. Lee BY, Singh A, David MZ, et al. The economic burden of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). Clin Microbiol Infect. 2013;19:528–536.
14. Talan DA, Krishnadasan A, Gorwitz RJ, et al. Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008. Clin Microbiol Infect. 2011;53:144–149.
15. Noskin GA, Rubin RJ, Schentag JJ, et al. National trends in Staphylococcus aureus infection rates: impact on economic burden and mortality over a 6-year period (1998–2003). Clin Microbiol Infect. 2007;45:1132–1140.
16. Diekema DJ, Pfaller MA, Schmitz FJ, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin Microbiol Infect. 2001;32 suppl 2:S114–S132.
17. Gould IM, Reilly J, Bunyan D, Walker A. Costs of healthcare- associated methicillin-resistant Staphylococcus aureus and its control. Clin Microbiol Infect. 2010;16:1721–1728.
18. Sader HS, Flamm RK, Jones RN. Antimicrobial activity of daptomycin tested against Gram-positive pathogens collected in Europe, Latin America, and selected countries in the Asia-Pacific Region (2011). Diagn Microbiol Infect Dis. 2013;75:417–422.
19. Miller LG, Diep BA. Clinical practice: colonization, fomites, and virulence: rethinking the pathogenesis of community- associated methicillin-resistant Staphylococcus aureus infection. Clin Microbiol Infect. 2008;46:752–760.
20. Muto CA, Jernigan JA, Ostrowsky BE, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol. 2003;24:362–386.
21. Aiello AE, Lowy FD, Wright LN, Larson EL. Meticillin-resistant Staphylococcus aureus among US prisoners and military personnel: review and recommendations for future studies. Lancet Infect Dis. 2006;6:335–341.
22. Miller LS, Cho JS. Immunity against Staphylococcus aureus cutaneous infections. Nat Rev Immunol. 2011;11:505–518.
23. Dinauer MC, Orkin SH, Brown R, Jesaitis AJ, Parkos CA. The glycoprotein encoded by the X-linked chronic granulomatous disease locus is a component of the neutrophil cytochrome b complex. Nature. 1987;327:717–720.
24. Winkelstein JA, Marino MC, Johnston RB, Jr, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore). 2000;79:155–169.
25. Ben-Ari J, Wolach O, Gavrieli R, Wolach B. Infections associated with chronic granulomatous disease: linking genetics to phenotypic expression. Expert Rev Anti Infect Ther. 2012;10:881–894.
26. Ong PY, Leung DY. The infectious aspects of atopic dermatitis. Immunol Allergy Clin North Am. 2010;30:309–321.
27. Minegishi Y, Saito M. Cutaneous manifestations of Hyper IgE syndrome. Allergol Int. 2012;61:191–196.
28. Davis SD, Schaller J, Wedgwood RJ. Job’s Syndrome. Recurrent, “cold”, staphylococcal abscesses. Lancet. 1966;1:1013–1015.
29. Kluytmans JA, Wertheim HF. Nasal carriage of Staphylococcus aureus and prevention of nosocomial infections. Infection. 2005;33:3–8.
30. Savage JW, Anderson PA. An update on modifiable factors to reduce the risk of surgical site infections. Spine J. 2013;13:1017–1029.
31. Huang SS, Septimus E, Kleinman K, et al. Targeted versus Universal Decolonization to Prevent ICU Infection. N Engl J Med. 2013;369:587.
32. Fritz SA, Hogan PG, Camins BC, et al. Mupirocin and chlorhexidine resistance in Staphylococcus aureus in patients with community-onset skin and soft tissue infections. Antimicrob Agents Chemother. 2013;57:559–568.
33. Kim HK, Thammavongsa V, Schneewind O, Missiakas D. Recurrent infections and immune evasion strategies of Staphylococcus aureus. Curr Opin Microbiol. 2012;15:92–99.
34. Ogston A, Witte W. On abscesses. Rev Infect Dis. 1984;6:122–128.
35. Kellaway CH, Tebbutt AH. Royal commission of inquiry into fatalities at Bundaberg. Report of the Royal Commission of Inquiry into Fatalities at Bundaberg. 1928.
36. Burnet FM. The exotoxins of staphylococcus pyogenes aureus. J Pathol Bacteriol. 1929;32:717–734.
37. Weise EC. Staphylococcus toxin in the treatment of furunculosis: preliminary report. JAMA. 1930;95:324–326.
38. Farrell LN. The potency of staphylococcal toxoid. J Immunol. 1941;41:119–126.
39. Dolman CE. Staphylococcus antitoxic serum in the treatment of acute staphylococcal infections and tox ae mias. Can Med Assoc J. 1934;31:130–135.
40. Chambers HF, Deleo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol. 2009;7:629–641.
41. Saravolatz LD, Markowitz N, Arking L, Pohlod D, Fisher E. Methicillin-resistant Staphylococcus aureus. Epidemiologic observations during a community-acquired outbreak. Ann Intern Med. 1982;96:11–16.
42. From the Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin- resistant Staphylococcus aureus—Minnesota and North Dakota, 1997–1999. JAMA. 1999;282:1123–1125.
43. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin- resistant Staphylococcus aureus infections in the United States. JAMA. 2007;298:1763–1771.
44. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309–317.
45. Bayer AS, Schneider T, Sahl HG. Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann N Y Acad Sci. 2013;1277:139–158.
46. Richter SS, Heilmann KP, Dohrn CL, et al. Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009. Antimicrob Agents Chemother. 2011;55:4154–4160.
47. Kraft WG, Johnson PT, David BC, Morgan DR. Cutaneous infection in normal and immunocompromised mice. Infect Immun. 1986;52:707–713.
48. Sherertz RJ, Forman DM, Solomon DD. Efficacy of dicloxacillin- coated polyurethane catheters in preventing subcutaneous Staphylococcus aureus infection in mice. Antimicrob Agents Chemother. 1989;33:1174–1178.
49. Bunce C, Wheeler L, Reed G, Musser J, Barg N. Murine model of cutaneous infection with gram-positive cocci. Infect Immun. 1992;60:2636–2640.
50. Voyich JM, Otto M, Mathema B, et al. Is Panton-Valentine leukocidin the major virulence determinant in community- associated methicillin-resistant Staphylococcus aureus disease? J Infect Dis. 2006;194:1761–1770.
51. Kobayashi SD, Malachowa N, Whitney AR, et al. Comparative analysis of USA300 virulence determinants in a rabbit model of skin and soft tissue infection. J Infect Dis. 2011;204:937–941.
52. Prabhakara R, Foreman O, De Pascalis R, et al. Epicutaneous model of community-acquired Staphylococcus aureus skin infections. Infect Immun. 2013;81:1306–1315.
53. Adem PV, Montgomery CP, Husain AN, et al. Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. N Engl J Med. 2005;353:1245–1251.
54. Labandeira-Rey M, Couzon F, Boisset S, et al. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science. 2007;315:1130–1133.
55. Bubeck Wardenburg J, Bae T, Otto M, Deleo FR, Schneewind O. Poring over pores: alpha-hemolysin and Panton- Valentine leukocidin in Staphylococcus aureus pneumonia. Nature medicine. 2007;13:1405–1406.
56. Bubeck Wardenburg J, Patel RJ, Schneewind O. Surface proteins and exotoxins are required for the pathogenesis of Staphylococcus aureus pneumonia. Infect Immun. 2007;75:1040–1044.
57. Bubeck Wardenburg J, Schneewind O. Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med. 2008;205:287–294.
58. Inoshima I, Inoshima N, Wilke GA, et al. A Staphylococcus aureus pore-forming toxin subverts the activity of ADAM10 to cause lethal infection in mice. Nat Med. 2011;17:1310–1314.
59. Inoshima N, Wang Y, Bubeck Wardenburg J. Genetic requirement for ADAM10 in severe Staphylococcus aureus skin infection. J Invest Dermatol. 2012;132:1513–1516.
60. Powers ME, Kim HK, Wang Y, Bubeck Wardenburg J. ADAM10 mediates vascular injury induced by Staphylococcus aureus alpha-hemolysin. J Infect Dis. 2012;206:352–356.
61. DeLeo FR, Kennedy AD, Chen L, et al. Molecular differentiation of historic phage-type 80/81 and contemporary epidemic Staphylococcus aureus. Proc Natl Acad Sci U S A. 2011;108:18091–18096.
62. Thurlow LR, Joshi GS, Richardson AR. Virulence strategies of the dominant USA300 lineage of communityassociated methicillin-resistant Staphylococcus aureus (CA-MRSA). FEMS Immunol Med Microbiol. 2012;65:5–22.
63. Fritz SA, Hogan PG, Hayek G, et al. Staphylococcus aureus colonization in children with community-associated Staphylococcus aureus skin infections and their household contacts. Arch Pediatr Adolesc Med. 2012;166:551–557.
64. Krishna S, Miller LS. Innate and adaptive immune responses against Staphylococcus aureus skin infections. Semin Immunopathol. 2012;34:261–280.
65. Foster TJ. Immune evasion by staphylococci. Nat Rev Microbiol. 2005;3:948–958.
66. Krishna S, Miller LS. Host-pathogen interactions between the skin and Staphylococcus aureus. Curr Opin Microbiol. 2012;15:28–35.
67. Kebaier C, Chamberland RR, Allen IC, et al. Staphylococcus aureus alpha-hemolysin mediates virulence in a murine model of severe pneumonia through activation of the NLRP3 inflammasome. J Infect Dis. 2012;205:807–817.
68. Nizet V. Understanding how leading bacterial pathogens subvert innate immunity to reveal novel therapeutic targets. J Allergy Clin Immunol. 2007;120:13–22.
69. O’Riordan K, Lee JC. Staphylococcus aureus capsular polysaccharides. Clin Microbiol Rev. 2004;17:218–234.
70. Silverman GJ, Goodyear CS. Confounding B-cell defences: lessons from a staphylococcal superantigen. Nat Rev Immunol. 2006;6:465–475.
71. Rooijakkers SH, Ruyken M, Roos A, et al. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nat Immunol. 2005;6:920–927.
72. Rooijakkers SH, van Wamel WJ, Ruyken M, van Kessel KP, van Strijp JA. Anti-opsonic properties of staphylokinase. Microbes Infect. 2005;7:476–484.
73. Archer NK, Mazaitis MJ, Costerton JW, et al. Staphylococcus aureus biofilms: properties, regulation, and roles in human disease. Virulence. 2011;2:445–459.
74. Tuchscherr L, Medina E, Hussain M, et al. Staphylococcus aureus phenotype switching: an effective bacterial strategy to escape host immune response and establish a chronic infection. EMBO Mol Med. 2011;3:129–141.
75. Yoong P, Torres VJ. The effects of Staphylococcus aureus leukotoxins on the host: cell lysis and beyond. Curr Opin Microbiol. 2013;16:63–69.
76. Bestebroer J, De Haas CJ, Van Strijp JA. How microorganisms avoid phagocyte attraction. FEMS Microbiol Rev. 2010;34:395–414.
77. Otto M. Basis of virulence in community-associated methicillin-resistant Staphylococcus aureus. Ann Rev Microbiol. 2010;64:143–162.
78. McCormick JK, Yarwood JM, Schlievert PM. Toxic shock syndrome and bacterial superantigens: an update. Ann Rev Microbiol. 2001;55:77–104.
79. DeDent A, Kim HK, Missiakas D, Schneewind O. Exploring Staphylococcus aureus pathways to disease for vaccine development. Semin Immunopathol. 2012;34:317–333.
80. Proctor RA. Challenges for a universal Staphylococcus aureus vaccine. Clin Infect Dis. 2012;54:1179–1186.
81. Spellberg B, Daum R. Development of a vaccine against Staphylococcus aureus. Semin Immunopathol. 2012;34:335–348.
82. Bagnoli F, Bertholet S, Grandi G. Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trials. Front Cell Infect Microbiol. 2012;2:16.
83. Robbins JB, Schneerson R, Horwith G, Naso R, Fattom A. Staphylococcus aureus types 5 and 8 capsular polysaccharide-protein conjugate vaccines. Am Heart J. 2004;147:593–598.
84. Shinefield H, Black S, Fattom A, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med. 2002;346:491–496.
85. Intercell. Merck and Intercell AG announce termination of phase II/III clinical trial of investigational Staphylococcus aureus vaccine, V7102011.
86. Fritz SA, Tiemann KM, Hogan PG, et al. A serologic correlate of protective immunity against communityonset Staphylococcus aureus infection. Clin Infect Dis. 2013;56:1554–1561.
87. Kennedy AD, Bubeck Wardenburg J, Gardner DJ, et al. Targeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J Infect Dis. 2010;202:1050–1058